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Is prostate-specific antigen (PSA) screening
indicated for any subgroup of men?
EVIDENCE-BASED ANSWER
Although African American men, men with a first-
degree relative with prostate cancer (CaP), and older
men constitute higher-risk subgroups, no well-
designed randomized controlled trials are available
that show PSA testing to improve mortality or quali-
ty of life for these or any other groups of men.1 A
trend toward detecting more localized cancers and a
possible decreasing mortality rate from CaP in all
men may be related to PSA testing, lead-time bias, or
both. (Grade of recommendation: C, based on inad-
equate reference standards and an unclear clinical
decision rule.)
EVIDENCE SUMMARY
The value of screening with PSA in any population is
uncertain. This issue will remain controversial at least
until the first of 2 well-designed randomized con-
trolled trials reports results in 2004.2,3 However, high-
er-risk subgroups merit special attention. Screening
the 3 groups mentioned above would improve the
positive predictive value of PSA, but crucial data to
determine whether this will improve outcomes are
lacking. Using average estimates, if 3300 African
American men (aged 50 to 65 years) were screened,
100 would have cancer. After subsequent radical
prostatectomy, 1 screened man would die from the
procedure, 60 would become impotent, and 20
would be incontinent.4
If current therapies for localized therapy do not
decrease morbidity or mortality, screening higher-risk
groups merely puts them at increased risk for poten-
tially harmful interventions. Biopsies cannot reliably
predict which cancers will progress and which will
lie indolent. The 30% incidence of CaP on autopsy
means that more people die with CaP than from it.
Using estimates of the prevalence and natural histo-
ry of the disease, decision analyses report varying
years saved by screening compared with watchful
waiting (ranging from a gain of 2.5 quality-adjusted
life years (QALYs) to an actual decrease in QALYs,
depending primarily on the rate of progression to
metastatic disease and efficacy of treatment.5,6
Another decision analysis, using quality-of-life mea-
sures, concluded that men would favor screening
only if the prevalence of CaP were greater than any
current estimate.7 Since the mean expected survival
at age 70 is slightly more than 10 years, PSA screen-
ing for men 70 years or older to detect cancers with
a 10-year survival rate of approximately 90% makes
little sense.  
RECOMMENDATIONS FROM OTHERS
The US Preventive Services Task Force in 1996 rec-
ommended against performing routine screening,
stating that there was fair evidence to exclude the
test. The American Cancer Society (ACS) and the
American Urological Association (AUA) recommend
that PSA be offered annually, beginning at patient
age 50, to men with a life expectancy of more than
10 years. The same recommendation extends to
younger African American men (age 40 years [AUA]
or 45 years [ACS]) and men with 1 (AUA) or 2 (ACS)
affected first-degree relatives. The American College
of Physicians and the American Academy of Family
Physicians (AAFP) recommend a discussion of the
benefits and harms of screening, diagnosis and treat-
ment, and individualizing the decision to screen.
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CLINICAL COMMENTARY
When ordering a PSA test, note the last time the
patient ejaculated. Ejaculation within 48 hours may
elevate PSA levels, as may prostatitis, urinary reten-
tion, and prostatic massage, although a digital exam-
ination does not. Finasteride and herbal remedies
such as saw palmetto can lower PSA levels.
In practice, it is helpful to follow the guidelines
from the AAFP, which advises counseling the patient
about the known risks and uncertain benefits of the
test (http://www.familydoctor.org/healthfacts/361/).
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